714 related articles for article (PubMed ID: 34624222)
1. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment.
Lam KC; Araya RE; Huang A; Chen Q; Di Modica M; Rodrigues RR; Lopès A; Johnson SB; Schwarz B; Bohrnsen E; Cogdill AP; Bosio CM; Wargo JA; Lee MP; Goldszmid RS
Cell; 2021 Oct; 184(21):5338-5356.e21. PubMed ID: 34624222
[TBL] [Abstract][Full Text] [Related]
2.
Si W; Liang H; Bugno J; Xu Q; Ding X; Yang K; Fu Y; Weichselbaum RR; Zhao X; Wang L
Gut; 2022 Mar; 71(3):521-533. PubMed ID: 33685966
[TBL] [Abstract][Full Text] [Related]
3. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Derived Retinoic Acid Regulates Intratumoral Monocyte Differentiation to Promote Immune Suppression.
Devalaraja S; To TKJ; Folkert IW; Natesan R; Alam MZ; Li M; Tada Y; Budagyan K; Dang MT; Zhai L; Lobel GP; Ciotti GE; Eisinger-Mathason TSK; Asangani IA; Weber K; Simon MC; Haldar M
Cell; 2020 Mar; 180(6):1098-1114.e16. PubMed ID: 32169218
[TBL] [Abstract][Full Text] [Related]
5. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
6. Ectopic expression of cGAS in
Waanders L; van der Donk LEH; Ates LS; Maaskant J; van Hamme JL; Eldering E; van Bruggen JAC; Rietveld JM; Bitter W; Geijtenbeek TBH; Kuijl CP
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072345
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling.
Shi Y; Zheng W; Yang K; Harris KG; Ni K; Xue L; Lin W; Chang EB; Weichselbaum RR; Fu YX
J Exp Med; 2020 May; 217(5):. PubMed ID: 32142585
[TBL] [Abstract][Full Text] [Related]
8. IL-32γ potentiates tumor immunity in melanoma.
Gruber T; Kremenovic M; Sadozai H; Rombini N; Baeriswyl L; Maibach F; Modlin RL; Gilliet M; von Werdt D; Hunger RE; Seyed Jafari SM; Parisi G; Abril-Rodriguez G; Ribas A; Schenk M
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32841222
[TBL] [Abstract][Full Text] [Related]
9. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation.
Milling LE; Garafola D; Agarwal Y; Wu S; Thomas A; Donahue N; Adams J; Thai N; Suh H; Irvine DJ
Cancer Immunol Res; 2022 Jan; 10(1):26-39. PubMed ID: 34686488
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
12. Beneficial bacteria activate type-I interferon production via the intracellular cytosolic sensors STING and MAVS.
Gutierrez-Merino J; Isla B; Combes T; Martinez-Estrada F; Maluquer De Motes C
Gut Microbes; 2020 Jul; 11(4):771-788. PubMed ID: 31941397
[TBL] [Abstract][Full Text] [Related]
13. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
14. Modulation of innate immunity in the tumor microenvironment.
Gonzalez-Gugel E; Saxena M; Bhardwaj N
Cancer Immunol Immunother; 2016 Oct; 65(10):1261-8. PubMed ID: 27344341
[TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil efficacy requires anti-tumor immunity triggered by cancer-cell-intrinsic STING.
Tian J; Zhang D; Kurbatov V; Wang Q; Wang Y; Fang D; Wu L; Bosenberg M; Muzumdar MD; Khan S; Lu Q; Yan Q; Lu J
EMBO J; 2021 Apr; 40(7):e106065. PubMed ID: 33615517
[TBL] [Abstract][Full Text] [Related]
16. STING Sensing of Murine Cytomegalovirus Alters the Tumor Microenvironment to Promote Antitumor Immunity.
Wilski NA; Stotesbury C; Del Casale C; Montoya B; Wong E; Sigal LJ; Snyder CM
J Immunol; 2020 Jun; 204(11):2961-2972. PubMed ID: 32284333
[TBL] [Abstract][Full Text] [Related]
17. A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells.
Haegel H; Thioudellet C; Hallet R; Geist M; Menguy T; Le Pogam F; Marchand JB; Toh ML; Duong V; Calcei A; Settelen N; Preville X; Hennequi M; Grellier B; Ancian P; Rissanen J; Clayette P; Guillen C; Rooke R; Bonnefoy JY
MAbs; 2013; 5(5):736-47. PubMed ID: 23924795
[TBL] [Abstract][Full Text] [Related]
18. Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer.
Lee SE; Jang GY; Lee JW; Park SH; Han HD; Park YM; Kang TH
Cancer Immunol Immunother; 2022 Dec; 71(12):3029-3042. PubMed ID: 35610387
[TBL] [Abstract][Full Text] [Related]
19. Immunostimulatory silica nanoparticle boosts innate immunity in brain tumors.
Bielecki PA; Lorkowski ME; Becicka WM; Atukorale PU; Moon TJ; Zhang Y; Wiese M; Covarrubias G; Ravichandran S; Karathanasis E
Nanoscale Horiz; 2021 Feb; 6(2):156-167. PubMed ID: 33400743
[TBL] [Abstract][Full Text] [Related]
20. Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity.
Karimi K; Karimi Y; Chan J; Boudreau JE; Basset J; Chew MV; Reid S; Bramson JL; Wan Y; Ashkar AA
Innate Immun; 2015 Aug; 21(6):626-34. PubMed ID: 25749844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
